Tigecycline: A new antibiotic

Intensive and Critical Care Nursing

Volumn 24, Issue 4, 2008, Pages 260-263

  Hylands, Jane ^a  

^a Wrightington Wigan and Leigh NHS Trust   (United Kingdom)

Author keywords

Antibiotic; Review; Tigecycline

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; MINOCYCLINE; TIGECYCLINE;

BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; CRITICAL ILLNESS; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG MONITORING; EUROPE; HUMAN; INTENSIVE CARE; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; PATIENT SELECTION; REVIEW; SOFT TISSUE INFECTION; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL CARE; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GREAT BRITAIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PATIENT SELECTION; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 52249105085     PISSN: 09643397     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iccn.2008.03.006     Document Type: Review

References (6)

1. Breedt J., Teras J., Gardovskis J., et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double blind phase 3 comparison study with vancomycin and aztreonam. Antimicrobial Agents and Chemotherapy 49 (2005) 4658-4666
2. Formin P., Beuran M., Gradauskas A., et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. International Journal of Surgery 3 (2005) 35-47
3. Olivia ME, Rekha A, Yellin A. et al. A muticentre trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infectious Diseases 2005; 5:88. Available at www.biomedcentral.com/1471-2334-5-88.
4. Sacchidanand S., Penn R.L., Embil J.M., et al. Effiacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam on patients with complicated skin and skin structure infections: results from a phase 3, randomised, double blind trial. International Journal of Infectious diseases 9 (2005) 251-261
5. Sader H., Jones R., Dowzicky M., et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalised in the intensive care unit. Diagnostic Microbiology and Infectious Disease 52 (2005) 203-208
6. Summary of Product Characteristics-Tygacil™. Wyeth Pharmaceuticals. May, 2006.